Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 20/20 | 0.60 |
| ▸ | BCL2 | P10415 | 11/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 11/20 | 0.60 |
| ▸ | BCL2A1 | Q16548 | 8/20 | 0.60 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.54 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995965 | 0.86 | BCL2L1 (0.66) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995970 | 0.84 | BCL2L1 (0.64) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL13018818 | 0.81 | BCL2L1 (0.55) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2529200 | 0.81 | BCL2L1 (0.58) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2528280 | 0.78 | BCL2L1 (0.61) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995986 | 0.77 | BCL2L1 (0.46) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL14995975 | 0.77 | HSPA5 (0.40) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2532050 | 0.77 | BCL2L1 (0.76) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL10130241 | 0.76 | BCL2L1 (0.61) | BCL2L1BCL2MCL1BCL2A1BCL2L2 | |
| SCHEMBL2530382 | 0.76 | BCL2L1 (0.55) | BCL2L1BCL2MCL1BCL2A1BCL2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455540-B2 | Gossypol and apogossypol derivatives, preparation thereof and uses thereof | UNIVERSITE DU MAINE (LE MANS) (FR) | 2013-06-04 | — | — | US | disclosed |
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163805-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | UNIVERSITE DU MAINE (LE MANS) (FR) | 2010-12-30 | — | — | US | disclosed |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | GEORGETOWN UNIVERSITY | 2009-04-09 | — | — | US | disclosed |
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | GEORGETOWN UNIVERSITY | 2009-04-09 | — | — | US | disclosed |
| US-20090082424-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | REGENTS OF THE UNIVERSITY OF MICHIGAN, THE | 2009-03-26 | — | — | US | disclosed |
| US-20090082424-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | REGENTS OF THE UNIVERSITY OF MICHIGAN, THE | 2009-03-26 | — | — | US | disclosed |
| US-7432304-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432304-B2 | Small molecule antagonists of Bcl-2 family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092684-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885MCL1 34/4885 |
| US-20100069344-A1 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS | BCL2L1, BCL2, BCL2L11 | BCL2L1 1/4885BCL2 2/4885MCL1 45/4885 |
| US-20090082424-A1 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885BCL2 1/4885MCL1 34/4885 |
| US-20100331398-A1 | DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS | LSS, GRHPR, NR1H3 | BCL2L1 1749/4885BCL2 3236/4885MCL1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.